Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 18513146.
- Also identified by DOI 10.1086/588794.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.
Medical subject headings
- Anti-HIV Agents
- Oligopeptides
- Organic Chemicals
- Plasma
- Pyridines